Clinical Trial: A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naive Patients.

U.S., June 2 -- ClinicalTrials.gov registry received information related to the study (NCT07619131) titled 'A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naive Patients.' on May 26.

Brief Summary: This is a study to evaluate the effect on LDL-C and the safety and tolerability of FDC laroprovstat/rosuvastatin in LLT-naive patients. Laroprovstat is a small molecule that reduces the amount of LDL-C in the blood. Laroprovstat and FDC laroprovstat/rosuvastatin are being developed for the treatment of hypercholesterolaemia.

Study Start Date: Aug. 17

Study Type: INTERVENTIONAL

Condition: Hypercholesterolaemia

Intervention: DRUG: Laroprovstat

dail...